Both Cellectis S.A. (NASDAQ:CLLS) and AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) are each other’s competitor in the Biotechnology industry. Thus the compare of their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis S.A.	21.43M	38.18	78.69M	-2.11	0.00
AMAG Pharmaceuticals Inc.	474.00M	0.92	169.34M	-4.92	0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Cellectis S.A. and AMAG Pharmaceuticals Inc.

Profitability

Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

	Net Margins	Return on Equity	Return on Assets
Cellectis S.A.	-367.20%	-23%	-18.8%
AMAG Pharmaceuticals Inc.	-35.73%	-29.5%	-13.2%

Volatility and Risk

Cellectis S.A. has a beta of 1.74 and its 74.00% more volatile than S&P 500. AMAG Pharmaceuticals Inc. has a 0.43 beta and it is 57.00% less volatile than S&P 500.

Liquidity

The Current Ratio and a Quick Ratio of Cellectis S.A. are 11.2 and 11.2. Competitively, AMAG Pharmaceuticals Inc. has 2.9 and 2.7 for Current and Quick Ratio. Cellectis S.A.’s better ability to pay short and long-term obligations than AMAG Pharmaceuticals Inc.

Analyst Recommendations

The following table shown below contains the ratings and recommendations for Cellectis S.A. and AMAG Pharmaceuticals Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Cellectis S.A.	0	2	1	2.33
AMAG Pharmaceuticals Inc.	1	1	0	2.50

Cellectis S.A. has an average price target of $35.25, and a 80.58% upside potential. Competitively the consensus price target of AMAG Pharmaceuticals Inc. is $16, which is potential 28.00% upside. The information presented earlier suggests that Cellectis S.A. looks more robust than AMAG Pharmaceuticals Inc. as far as analyst view.

Insider and Institutional Ownership

Roughly 29.4% of Cellectis S.A. shares are held by institutional investors while 0% of AMAG Pharmaceuticals Inc. are owned by institutional investors. Competitively, insiders own roughly 0.2% of AMAG Pharmaceuticals Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Cellectis S.A.	12.66%	10.81%	-10.39%	-33.67%	-37.98%	17.6%
AMAG Pharmaceuticals Inc.	-4.11%	-8.8%	-17.01%	-39.19%	-27.17%	-1.71%

For the past year Cellectis S.A. has 17.6% stronger performance while AMAG Pharmaceuticals Inc. has -1.71% weaker performance.

Summary

On 7 of the 12 factors Cellectis S.A. beats AMAG Pharmaceuticals Inc.

Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL) and CLL. The companyÂ’s products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-cell ALL and MM. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc. to generate CAR T-cells in the field of oncology; Les Laboratoires Servier SAS to develop and commercialize product candidates; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for womenÂ’s health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families. In addition, it has a option agreement with Velo to acquire the rights to digoxin immune fab, a polyclonal antibody in clinical development for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. It has a license agreement with Palatin Technologies, Inc. to research, develop, and commercialize Rekynda, an investigational product designed to be an on-demand treatment for hypoactive sexual desire disorder in pre-menopausal women, as well as with Endoceutics, Inc. to develop and commercialize pharmaceutical products with dehydroepiandrosterone; and development and license agreement with Antares Pharma, Inc. to develop, use, sell, and offer for sale and import and export the Makena auto-injector. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.